Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT. 

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Feliza Mirasol is the science editor for 

CPHI Milan 2024: Industry Trends Impacting Oral Solid Dose Formulation

Articles

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.

CMOs and Hybrid Companies Predicted to Hold 54% of Biologics Capacity in 2028, According to CPHI Annual Survey

The nanofiber microcarriers are the first of their kind for manufacturing viral vectors used in gene therapy production, according to Cellevate.

Cellevate Plans Pre-Launch of First Nanofiber Microcarriers for Viral Vector Manufacturing at CPHI Milan

Contract organizations offer assistance for testing raw materials obtained from outside suppliers.

Contractors Support Material Testing

As part of a range of sustainable products and services that SGD Pharma plans to showcase at CPHI Milan, the company will introduce its siliconized molded glass vials.

SGD Pharma to Introduce Siliconized Molded Glass Vials at CPHI Milan to Showcase Sustainable Packaging

According to the survey results, 49% of industry respondents are “highly positive” on the contract services sector seeing growth over the next 18 months.

Results from CPHI Milan Survey Find No Favor Among Industry for BIOSECURE Act While Predicting Faster Growth for CDMOs in 2025

Lonza signed a long-term supply agreement to manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

Lonza and Vertex Enter Commercial Supply Agreement for CASGEVY, the Sickle Cell Disease Gene-Edited Cell Therapy

Contract organizations offer assistance when managing changes to material suppliers during a product’s lifecycle.

Navigating a Material Supplier Change

Qualifying material suppliers is a crucial step in ensuring safe and effective drug products.